Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-2485 in advanced solid tumors
NCT05490472Phase 2Recruiting
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of JAB-2485 in solid tumor, estrogen receptor-positive breast cancer (ER+), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), sponsored by Jacobio Pharmaceuticals. Started Dec 2022; status: recruiting.
02
Drugs
JAB-2485
03
Conditions
solid tumorestrogen receptor-positive breast cancer (ER+)triple-negative breast cancer (TNBC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05490472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490472.